OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies said the FDA cleared its Colli-Pee™•Dx urine collection kit (from subsidiary DNA Genotek) for at-home first-void urine collection for Roche cobas 5800/6800/8800 molecular testing. The kit supports tests for Chlamydia, Gonorrhea, Trichomonas vaginalis, and Mycoplasma genitalium, enabling mail-in workflows and decentralized STI screening.
How this was made
The 30-second read
Why it matters
FDA clearance validates the kit for use with Roche cobas 5800/6800/8800 systems and for multiple STI targets, enabling scalable mail-in specimen workflows for high-throughput molecular testing.
Market read
Traders can treat this as a regulatory catalyst that de-risks decentralized STI testing adoption for OSUR’s collection-device business.
What to watch
Adoption depends on payer coverage, lab integration with Roche cobas platforms, and competitive collection-kit alternatives; the release doesn’t quantify uptake or pricing.
Background
OraSure’s Colli-Pee™•Dx is a urine collection kit intended to stabilize DNA/RNA for molecular STI testing, enabling at-home self-collection.
Ticker impact
OraSure received FDA clearance for its Colli-Pee™•Dx urine collection kit to pair with Roche cobas STI molecular testing systems.
Near-term upside bias as the clearance can support incremental commercial adoption; magnitude likely moderate absent revenue guidance.
This is a concrete regulatory approval tied to a specific product workflow (collection kit + Roche cobas platforms) and multiple STI targets, but the article provides no financial figures or near-term sales commitments.
Market effects
Supports read-across for point-of-need/home diagnostics and sample-management platforms as regulators clear more decentralized workflows.
Primarily US-focused adoption via FDA clearance for at-home urine collection.
May improve global commercialization prospects for decentralized STI screening models, though the clearance is explicitly US.
Counterpoint
Commercial impact may be slower than the regulatory milestone because labs/health systems must operationalize mail-in workflows and procurement cycles.
Key entities
- companyOraSure Technologies, Inc.
Developer of the Colli-Pee™•Dx urine collection kit cleared by the FDA for at-home STI sample collection.
- subsidiaryDNA Genotek Inc.
OraSure subsidiary that manufactures/sells the Colli-Pee™•Dx urine collection kit.
- partnerRoche
Provides cobas molecular diagnostic systems used to run the cleared STI tests.
- regulatorFDA
Cleared the Colli-Pee™•Dx urine collection kit for specified STI testing workflows.
